Browse by Poster Presenter

Type here to filter the list

A
Abdelgawad, Ibrahim

AbbVie
PII-051 - ELRANATAMAB INTEGRATED EXPOSURE-RESPONSE (ER) EFFICACY AND SAFETY ANALYSES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) USING A CLINICAL UTILITY INDEX (CUI)
Ibrahim Abdelgawad
Favorite
Abdelhady, Ahmed

Intellia Therapeutics
PII-121 - IMPLEMENTATION OF QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING IN TRANSLATION AND DOSE SELECTION FOR FIRST-IN-HUMAN PHASE 1/2 CLINICAL STUDY OF NTLA-2002 IN THE TREATMENT OF HEREDITARY ANGIOEDEMA
Ahmed Abdelhady
Favorite
Aboshady, Omar

College of Pharmacy, Purdue University
OAI-001 - CHANGES IN QTC ACROSS DIFFERENT TRIMESTERS OF PREGNANCY AND PRE-ECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Omar Aboshady
Favorite
PII-007 - CHANGES IN QTC ACROSS DIFFERENT TRIMESTERS OF PREGNANCY AND PRE-ECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Omar Aboshady
Favorite
Adeluola, Adeoluwa

The Ohio State University
PII-048 - APPARENT FCRN DYSFUNCTION IN CANCER CACHEXIA DECREASES EXTRAVASCULAR IMMUNOGLOBULIN G ABSORPTION.
Adeoluwa Adeluola
Favorite
Adeojo, Lilian

Arcus Biosciences Inc.
LB-022 - MULTIPLE ELIMINATION PATHWAYS ARE RESPONSIBLE FOR THE ELIMINATION OF ETRUMADENANT (ETRUMA) AFTER ORAL ADMINISTRATION OF [14C]-ETRUMA TO HUMANS.
Lilian Adeojo
Favorite
Akinola, Lois

U.S. Food and Drug Administration
PT-024 - EVIDENCE SUPPORTING EFFICACY EXTRAPOLATIONS FOR TARGETED THERAPIES ACROSS MOLECULARLY DEFINED SUBSETS OF DISEASES IN THE ABSENCE OF SUBSET-SPECIFIC CLINICAL DATA.
Lois Akinola
Favorite
PWI-004 - EVIDENCE SUPPORTING EFFICACY EXTRAPOLATIONS FOR TARGETED THERAPIES ACROSS MOLECULARLY DEFINED SUBSETS OF DISEASES IN THE ABSENCE OF SUBSET-SPECIFIC CLINICAL DATA.
Lois Akinola
Favorite
AL Nebaihi, Hamdah

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta
PII-183 - POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07265803 AND ITS METABOLITE IN PATIENTS WITH LAMIN A/C RELATED DILATED CARDIOMYOPATHY.
Hamdah AL Nebaihi
Favorite
Alaei, Samaneh

Abbvie Inc
PII-119 - IMPACT OF CRUSHING OR GRINDING ON THE RELATIVE BIOAVAILABILITY OF THE VENETOCLAX TABLETS.
Samaneh Alaei
Favorite
Almond, Lisa

Certara UK (Simcyp)
CT-006 - APPLICATION OF PBPK TO ASSESS THE IMPACT OF UGT1A1 GENOTYPE ON DOLUTEGRAVIR EXPOSURE IN PREGNANT WOMEN AND FETUSES
Lisa Almond
Favorite
CT-007 - APPLICATION OF PBPK TO SUPPLEMENT CLINICAL DATA AND INVESTIGATE THE IMPACT OF UGT1A1 PHENOTYPE ON DOLUTEGRAVIR EXPOSURE IN AFRICAN BREASTFED INFANTS
Lisa Almond
Favorite
PII-161 - APPLICATION OF PBPK TO ASSESS THE IMPACT OF UGT1A1 GENOTYPE ON DOLUTEGRAVIR EXPOSURE IN PREGNANT WOMEN AND FETUSES
Lisa Almond
Favorite
PII-162 - APPLICATION OF PBPK TO SUPPLEMENT CLINICAL DATA AND INVESTIGATE THE IMPACT OF UGT1A1 PHENOTYPE ON DOLUTEGRAVIR EXPOSURE IN AFRICAN BREASTFED INFANTS
Lisa Almond
Favorite
Alshameri, Naifah

University of Florida
PT-021 - DNA METHYLATION PATTERNS OF ARA-C, DAUNORUBICIN, AND ETOPOSIDE PHARMACOKINETIC/PHARMACODYNAMIC GENES ARE ASSOCIATED WITH THE CLINICAL OUTCOMES IN AML.
Naifah Alshameri
Favorite
Alshammari, Raed

College of Pharmacy, University of Florida
PT-006 - A GENOME-WIDE DNA METHYLATION ANALYSIS REVEALS DIFFERENT METHYLATION PATTERNS AND MECHANISTIC CLUES OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW.
Raed Alshammari
Favorite
B
B Ximenez, Joao Paulo

University of Sao Paulo
PII-038 - PK/PD OF RIFAMPICIN, ISONIAZID, PYRAZINAMIDE, AND ETHAMBUTOL IN MACROPHAGES INFECTED WITH M. TUBERCULOSIS.
Joao Paulo B Ximenez
Favorite
Back, Hyunmoon

Bristol Myers Squibb
PII-095 - A POPULATION PHARMACOKINETIC (PK) MODEL OF MILVEXIAN, A SMALL MOLECULE FACTOR XIA INHIBITOR, IN HEALTHY VOLUNTEERS.
Hyunmoon Back
Favorite
Bader, Justin

Bicycle Therapeutics
CT-012 - PHARMACOKINETICS OF BT8009, A BICYCLE TOXIN CONJUGATE (BTC), IN PATIENTS WITH SOLID TUMOR MALIGNANCIES AND VARIOUS DEGREES OF RENAL FUNCTIONS
Justin Bader
Favorite
PII-062 - PHARMACOKINETICS OF BT8009, A BICYCLE TOXIN CONJUGATE (BTC), IN PATIENTS WITH SOLID TUMOR MALIGNANCIES AND VARIOUS DEGREES OF RENAL FUNCTIONS
Justin Bader
Favorite
Bae, Jihyun

FDA
PII-186 - A SURVEY ON RECOMMENDATION OF FOOD CONDITIONS IN BIOEQUIVALENCE STUDIES WITH PHARMACOKINETIC ENDPOINTS FOR GENERIC ORAL ANTINEOPLASTIC DRUG DEVELOPMENT.
Jihyun Bae
Favorite
Baek, Seunghwan

Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital
CT-008 - EFFICACY AND SAFETY OF METFORMIN IN TYPE 2 DIABETIC PATIENTS WITH MILD HEPATIC IMPAIRMENTS: A RETROSPECTIVE COHORT STUDY USING PROPENSITY SCORE MATCHING METHOD.
Seunghwan Baek
Favorite
PII-201 - EFFICACY AND SAFETY OF METFORMIN IN TYPE 2 DIABETIC PATIENTS WITH MILD HEPATIC IMPAIRMENTS: A RETROSPECTIVE COHORT STUDY USING PROPENSITY SCORE MATCHING METHOD.
Seunghwan Baek
Favorite
Balazki, Pavel

esqlabs GmbH
PII-165 - AUTOMATED QUALIFICATION FRAMEWORK FOR PHYSIOLOGICALLY-BASED QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING
Pavel Balazki
Favorite
Barry, Jessica

University of Minnesota
PII-208 - UTILIZING STATISTICAL OR POPULATION PHARMACOKINETIC BASED MATCHING FOR VIRTUAL CONTROL GROUPS IN RENAL AND HEPATIC IMPAIRMENT STUDIES
Jessica Barry
Favorite
Bedathuru, Dinesh

Vantage Research
PII-218 - QSP MODEL OF RHEUMATOID ARTHRITIS, CAPTURING RANGE OF RESPONSES TO METHOTREXATE, ADALIMUMAB AND TOCILIZUMAB THERAPIES
Dinesh Bedathuru
Favorite
Bhamidipaty-Pelosi, Surya

Indiana University
TIP-004 - CHARACTERIZATION OF LABETALOL IN PREGNANCY (THE CLIP STUDY).
Surya Bhamidipaty-Pelosi
Favorite
Bhat, Laxminarayan

Reviva Pharmaceuticals Holdings Inc
LB-008 - BRILAROXAZINE EFFICACY AND SAFETY IN THE PHASE 3 RECOVER TRIAL IN ACUTE SCHIZOPHRENIA
Laxminarayan Bhat
Favorite
Bhatnagar, Roopal

Critical Path Institute
AI-004 - UNLOCKING HIDDEN DRUG-REPURPOSING OPPORTUNITIES: NLP-POWERED TOPIC MODELING OF UNSTRUCTURED CURE-ID DATA
Roopal Bhatnagar
Favorite
PII-225 - UNLOCKING HIDDEN DRUG-REPURPOSING OPPORTUNITIES: NLP-POWERED TOPIC MODELING OF UNSTRUCTURED CURE-ID DATA
Roopal Bhatnagar
Favorite
Bravo Padros, Marçal

Regeneron Pharmaceuticals, Inc.
PII-067 - POPULATION PHARMACOKINETICS OF ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.
Marçal Bravo Padros
Favorite
Burnett, Joseph

Bristol Myers Squibb
PII-178 - PROSPECTIVE APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING TO INFORM THE DESIGN OF A CLINICAL DRUG-DRUG INTERACTION (DDI) STUDY: CASE STUDY OF MEZIGDOMIDE
Joseph Burnett
Favorite
C
Callegari, Ernesto

Pfizer, Inc.
PII-176 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ZAVEGEPANT
Ernesto Callegari
Favorite
PII-177 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO EVALUATE THE GASTRIC ACID MODIFIER EFFECT ON RIMEGEPANT EXPOSURE
Ernesto Callegari
Favorite
Cardona, Panli

Amgen, Inc
PII-047 - AN OPEN-LABEL BIOEQUIVALENCE STUDY IN HEALTHY VOLUNTEERS TO COMPARE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET STRENGTHS OF SOTORASIB IN THE FED AND FASTED STATE
Panli Cardona
Favorite
Carver, Kathryn

Northwestern University
PII-079 - IDENTIFYING EPIGENTIC INFLUENCES ON DRUG METABOLISM: MULTI-OMIC ANALYSES IN AFRICAN AMERICAN HEPATOCYTES
Kathryn Carver
Favorite
Chae, Woori

Seoul National University
PII-005 - A NOVEL ENDOTYPE OF ADULT ASTHMA SUGGESTED BY PLASMA METABOLITE PROFILING OF THE COHORT FOR REALITY AND EVOLUTION OF ADULT ASTHMA IN KOREA (COREA)
Woori Chae
Favorite
Chang, Min Jung

Yonsei University
AI-006 - DEEP LEARNING PREDICTION OF VANCOMYCIN TIME-CONCENTRATION LEVELS IN NEONATES
Min Jung Chang
Favorite
LB-010 - DEEP LEARNING PREDICTION OF VANCOMYCIN TIME-CONCENTRATION LEVELS IN NEONATES
Min Jung Chang
Favorite
Channavazzala, Madhav

Vantage Research
PII-212 - A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR PREDICTING EFFICACY FOR A COMBINATION OF AN ANTIBODY DRUG CONJUGATE (ADC) AND A CHECKPOINT INHIBITOR (CPI) IN PHASE II/III CLINICAL TRIALS
Madhav Channavazzala
Favorite
Chekka, Lakshmi Manasa

U.S. Food and Drug Administration
PT-015 - EVALUATING THE UTILITY OF PROTEOMICS FOR IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILARITY - USING PCSK-9 INHIBITOR BIOLOGICS AS A CASE STUDY
Lakshmi Manasa Chekka
Favorite
PWII-002 - EVALUATING THE UTILITY OF PROTEOMICS FOR IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILARITY - USING PCSK-9 INHIBITOR BIOLOGICS AS A CASE STUDY
Lakshmi Manasa Chekka
Favorite
Cheng, Yiming

Bristol Myers Squibb
AI-001 - APPLICATION OF GAUSSIAN PROCESS MODEL IN LONGITUDINAL PHARMACOKINETIC/PHARMACODYNAMIC DATA AND COMPARISON WITH NATURAL LANGUAGE PROCESSING MODELS
Yiming Cheng
Favorite
PII-098 - APPLICATION OF GAUSSIAN PROCESS MODEL IN LONGITUDINAL PHARMACOKINETIC/PHARMACODYNAMIC DATA AND COMPARISON WITH NATURAL LANGUAGE PROCESSING MODELS
Yiming Cheng
Favorite
Chen, Huili

Univ of Florida Coll of Pharmacy
LB-037 - UTILIZING MODEL BASED META-ANALYSIS TO CHARACTERIZE BREAKTHROUGH BLEEDING AND SPOTTING IN WOMEN USING HORMONAL CONTRACEPTIVES
Huili Chen
Favorite
Chen, Jie

University of Houston
LB-034 - THE POPULATION PHARMACOKINETICS STUDY OF ANTI-TUMOR B AMONG HEALTHY VOLUNTEER AND ORAL CANCER PATIENTS TO INFORM DOSE DECISION
Jie Chen
Favorite
Chen, Min

Bristol Myers Squibb
PII-027 - FORMULATION IMPACT OF SSZ ON MTX EXPOSURE: A REPEAT DDI STUDY FOR A MK2 INHIBITOR BMS-986371
Min Chen
Favorite
Chen, Yizhe

Clinical pharmacology and pharmacometrics, disposition and bioanalysis
PII-116 - EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Yizhe Chen
Favorite
Cilliers, Cornelius

Mirati Therapeutics
PII-195 - A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL HEPATIC FUNCTION.
Cornelius Cilliers
Favorite
PII-196 - A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL RENAL FUNCTION.
Cornelius Cilliers
Favorite
Clemens, Lara

Simulations Plus, Inc.
PII-210 - A BIOMARKER-FOCUSED QSP MODEL OF COMPLEMENT ALTERNATIVE AND TERMINAL PATHWAYS TO EVALUATE POTENTIAL TARGETS FOR THERAPEUTIC IMPACT IN COMPLEMENT-ASSOCIATED DISEASES: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS A CASE STUDY.
Lara Clemens
Favorite
Collins, Keagan

Pfizer, Inc.
PII-064 - POPULATION PHARMACOKINETIC MODEL FOR THE TGFβR1 INHIBITOR PF-06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Keagan Collins
Favorite
Collins, Kimberly

Critical Path Institute
PII-008 - C-PEPTIDE DISEASE PROGRESSION MODEL IN INDIVIDUALS WITH NEW-ONSET TYPE 1 DIABETES
Kimberly Collins
Favorite
Crass, Ryan

Apellis Pharmaceuticals
PII-096 - A TRANSLATIONAL MODELING AND SIMULATION APPROACH TO INFORM FIRST-IN-HUMAN DOSE SELECTION FOR AN SIRNA TARGETING COMPLEMENT C3.
Ryan Crass
Favorite
PWI-002 - A TRANSLATIONAL MODELING AND SIMULATION APPROACH TO INFORM FIRST-IN-HUMAN DOSE SELECTION FOR AN SIRNA TARGETING COMPLEMENT C3.
Ryan Crass
Favorite
D
Damian, Valeriu

GSK
PII-222 - VALIDATION OF A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL FOR CHRONIC HEPATITIS B.
Valeriu Damian
Favorite
Das, Sharmila

Bristol Meyers Squibb
PII-057 - INTEGRATED PHARMACOKINETIC (PK)/PHARMACODYNAMIC MODELING OF PK, SAFETY, AND EFFICACY DATA TO SUPPORT DOSE OPTIMIZATION OF BMS-986158, A BROMODOMAIN AND EXTRA-TERMINAL INHIBITOR (BETI), IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF).
Sharmila Das
Favorite
Denney, William

Human Predictions
LB-016 - IMPROVED NONCOMPARTMENTAL HALF-LIFE ESTIMATION WITH TOBIT REGRESSION.
William Denney
Favorite
Der, Kenneth

Amgen
PII-093 - A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF A SINGLE DOSE OF DAZODALIBEP IN HEALTHY JAPANESE AND CAUCASIAN PARTICIPANTS.
Kenneth Der
Favorite
Desai, Devam

Center of Pharmacometrics and Systems Pharmacology, University of Florida
PII-219 - QUANTITATIVE CHARACTERIZATION OF ENHANCED TISSUE DISTRIBUTION AND INNATE KILLING POTENTIAL OF UN-ENGINEERED GAMMA DELTA Ɣδ T CELLS USING A MECHANISTIC MODEL
Devam Desai
Favorite
Desta, Zeruesenay

Indiana University School of Medicine
PII-090 - A PHARMACOKINETIC AND ENZYME TURNOVER MODEL PREDICTS MAJOR ROLES FOR CYP2B6 GENOTYPES ON THE MAGNITUDE OF EFAVIREZ AUTOINDUCTION OF METABOLISM AND CLEARNCE IN HEALTHY VOLUNTEERS
Zeruesenay Desta
Favorite
Devineni, Damayanthi

Johnson & Johnson Innovative Medicine
PII-097 - AN INTEGRATED ASSESSMENT OF THE AME PROPERTIES OF SELTOREXANT UTILIZING PRECLINICAL IN VITRO, IN VIVO, AND HUMAN ADME DATA.
Damayanthi Devineni
Favorite
Dilizia, Michele

Recce Pharmaceuticals Ltd
PII-037 - FIH STUDY OF INTRAVENOUS RECCE327: A NOVEL, BROAD SPECTRUM, SYNTHETIC ANTI-INFECTIVE
Michele Dilizia
Favorite
DJEBLI, Nassim

Luzsana Biotechnonology (subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd)
PII-105 - COMBINED PARENT AND PAYLOAD POPULATION PHARMACOKINETIC MODELING TO SUPPORT DOSE RECOMMENDATION OF THE NOVEL ANTI-TROP-2 ANTIBODY-DRUG CONJUGATE (ADC) SHR-A1921.
Nassim DJEBLI
Favorite
PII-126 - MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR) AND GRADE 3+ TREATMENT-RELATED ADVERSE EVENTS (G3TRAE) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC).
Nassim DJEBLI
Favorite
PII-146 - POPULATION PHARMACOKINETIC MODELING OF CAMRELIZUMAB IN PATIENTS WITH VARIOUS CANCER TYPES, INCLUDING ADVANCED HEPATOCELLULAR CARCINOMA.
Nassim DJEBLI
Favorite
PII-148 - POPULATION PHARMACOKINETIC MODELING OF RIVOCERANIB IN HEALTHY SUBJECTS AND PATIENTS WITH VARIOUS CANCER TYPES, INCLUDING ADVANCED HEPATOCELLULAR CARCINOMA (HCC).
Nassim DJEBLI
Favorite
PII-149 - POPULATION PHARMACOKINETICS AND TUMOR GROWTH INHIBITION MODELING OF AN ANTI-CLAUDIN 18.2 ADC TO SUPPORT DRUG DEVELOPMENT DECISION-MAKING
Nassim DJEBLI
Favorite
PII-151 - POPULATION PHARMACOKINETICS OF REZVILUTAMIDE (SHR3680) WITH TIME-VARYING AND SATURABLE RELATIVE BIOAVAILABLITY IN PROSTATE CANCER PATIENTS
Nassim DJEBLI
Favorite
Dogterom, Peter

QPS Netherlands
PII-029 - PHARMACOKINETIC EVALUATION OF GB1211 IN A NOVEL TABLET FORMULATION, ADMINISTERED UNDER FASTED AND FED CONDITIONS, AND COMPARED TO GB1211 CAPSULES, IN HEALTHY VOLUNTEERS
Peter Dogterom
Favorite
PII-030 - PHASE 1 EVALUATION OF THE SAFETY, TOLERABILITY AND PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF THE ADENOSINE A1R/A3R AGONIST AST-004 AFTER INTRAVENOUS INFUSION IN HEALTHY VOLUNTEERS
Peter Dogterom
Favorite
Dong, Shuai

Sarepta Therapeutics, Inc.
PII-139 - PHARMACOMETRICS-BASED APPROACH TO FIRST-IN-HUMAN INTRAVENOUS DOSE DETERMINATION FOR SRP-6004 IN PATIENTS WITH LIMB GIRDLE MUSCULAR DYSTROPHY 2B
Shuai Dong
Favorite
Drabison, Thomas

The Ohio State University
PII-156 - STRAIN- AND ROUTE-DEPENDENT PLASMA PHARMACOKINETICS AND BRAIN PENETRATION OF PACLITAXEL.
Thomas Drabison
Favorite
Du, Ping

U.S. Food and Drug Administration
PII-171 - IDENTIFY BIOPREDICTIVE DISSOLUTION FOR PREDICTING IN VIVO PERFORMANCE OF A BCS II DRUG PRODUCT UNDER FED CONDITION
Ping Du
Favorite
E
Elashkar, Omar

Department of Pharmaceutics, College of Pharmacy, University of Florida
PII-009 - DECIPHERING TYPE 1 DIABETES BY INTEGRATING ARTIFICIAL INTELLIGENCE WITH PANCREATIC WHOLE SLIDE IMAGING
Omar Elashkar
Favorite
Eltanameli, Bassma

University of Florida College of Pharmacy
LB-032 - PREDICTING THE POTENTIAL FOR CANNABIDIOL INDUCED DRUG-DRUG INTERACTIONS WITH MAJOR CYP450 ENZYMES USING MODEL-BASED APPROACHES
Bassma Eltanameli
Favorite
Evans, Martin

Walter Reed Army Institute of Research
PII-039 - PLERIXAFOR AS PATHOGEN AGNOSTIC PROPHYLAXIS OR ADVUVANT TREATMENT
Martin Evans
Favorite
Ezuruike, Udoamaka

Certara UK (Simcyp Division)
LB-003 - A NOVEL MECHANISTIC PHYSIOLOGICALLY BASED PHARMACOKINETIC-PHARMACODYNAMIC (PBPK-PD) MODEL TO ASSESS DRUG-DRUG INTERACTION (DDI) RISKS FOR ACID REDUCING AGENTS (ARA).
Udoamaka Ezuruike
Favorite
F
Franzese, Richard

GSK
PII-058 - MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) TO COMPARE PD-1 AND PD-L1 TREATMENT OUTCOMES IN METASTATIC (M) NON-SMALL-CELL LUNG CANCER (NSCLC)
Richard Franzese
Favorite
PWII-001 - MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) TO COMPARE PD-1 AND PD-L1 TREATMENT OUTCOMES IN METASTATIC (M) NON-SMALL-CELL LUNG CANCER (NSCLC)
Richard Franzese
Favorite
G
Garimella, Tushar

Quantitative Clinical Pharmacology, Daiichi-Sankyo, Inc
PII-117 - EXPOSURE-RESPONSE OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
Tushar Garimella
Favorite
PII-136 - PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
Tushar Garimella
Favorite
Gbadamosi, Mohammed

Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida
PT-005 - INTEGRATED GENOMICS AND TRANSCRIPTOMICS ANALYSES USING HAPMAP CELL LINES REVEAL NOVEL MODULATORS OF CELLULAR RESPONSE TO CYCLOPHOSPHAMIDE.
Mohammed Gbadamosi
Favorite
Gelineau-Morel, Rose

Children's Mercy Kansas City
PII-089 - STEREOSELECTIVE METABOLISM OF TRIHEXYPHENIDYL: THE PATHWAY TO PRECISION DOSING
Rose Gelineau-Morel
Favorite
Gershuny, Victoria

U.S. Food and Drug Administration
PII-026 - COMPARISON OF CHANGES IN PUPIL DIAMETER AND HYPERCAPNIC VENTILATION FOR OXYCODONE AND PSYCHOTROPIC DRUGS ADMINISTERED ALONE OR IN COMBINATION
Victoria Gershuny
Favorite
Ghasemi, Mohammad

Arcus Biosciences
PII-143 - POPULATION PHARMACOKINETIC (PK) MODEL OF AB521, A SMALL MOLECULE INHIBITOR OF HIF-2α, IN HEALTHY PARTICIPANTS.
Mohammad Ghasemi
Favorite
Ghent, Barbara

Arvinas Operations, Inc.
PII-109 - DRUG-DRUG INTERACTION (DDI) STUDY OF THE PROTEOLYSIS TARGETING CHIMERA (PROTAC) ANDROGEN RECEPTOR (AR) DEGRADER BAVDEGALUTAMIDE IN COMBINATION WITH THE P-GLYCOPROTEIN (P-GP) SUBSTRATE FEXOFENADINE IN HEALTHY MALE VOLUNTEERS.
Barbara Ghent
Favorite
Gibbons, Francis

Preclinical and Translational Sciences, Takeda Pharmaceuticals
PII-019 - COMPARISON OF METHODS OF FIRST-IN-HUMAN DOSE PREDICTION FOR ADENO-ASSOCIATED VIRUS-MEDIATED GENE THERAPIES IN FABRY DISEASE
Francis Gibbons
Favorite
PWI-001 - COMPARISON OF METHODS OF FIRST-IN-HUMAN DOSE PREDICTION FOR ADENO-ASSOCIATED VIRUS-MEDIATED GENE THERAPIES IN FABRY DISEASE
Francis Gibbons
Favorite
Gong, Jue

Janssen
PII-056 - IMMUNOGENICITY AND SBMCA CHANGE IN THE COMPARISON OF TALQUETAMAB RECOMMENDED PHASE 2 DOSES
Jue Gong
Favorite
Gooden, Felicia

Cincinnati Children's Hospital Medical Center/ University of Cincinnati
PII-081 - MISS SCORES VARY IN ACCORDANCE WITH SLCO1B1 STATUS IN A COHORT OF JIA PATIENTS
Felicia Gooden
Favorite
Grant, Caroline

Mayo Clinic
AI-003 - BRAIN MEASUREMENTS, PERIPHERAL BIOMARKERS, OR BOTH? IMPROVED PREDICTIONS OF RESPONSE TO SERTRALINE THROUGH MULTI-MODAL DATA INTEGRATION.
Caroline Grant
Favorite
PII-223 - BRAIN MEASUREMENTS, PERIPHERAL BIOMARKERS, OR BOTH? IMPROVED PREDICTIONS OF RESPONSE TO SERTRALINE THROUGH MULTI-MODAL DATA INTEGRATION.
Caroline Grant
Favorite
Gronich, Naomi

Clalit Health Services, and Rappaport Faculty of Medicine, Technion - Israel Institue of Technology
CT-005 - PREVALENCE, AGE AND SEX DISTRIBUTION OF PATIENTS WITH CHRONIC HEALTH CONDITIONS IN A LARGE HEALTHCARE SYSTEM
Naomi Gronich
Favorite
PII-023 - PREVALENCE, AGE AND SEX DISTRIBUTION OF PATIENTS WITH CHRONIC HEALTH CONDITIONS IN A LARGE HEALTHCARE SYSTEM
Naomi Gronich
Favorite
Gupta, Churni

University of Florida
PT-019 - ESTABLISHING A PARAMOUNT QUANTITATIVE FRAMEWORK LINKING DISEASE PROGRESSION AND CLINICAL OUTCOMES FOR PARKINSONS DISEASE
Churni Gupta
Favorite
Gupta, Pawan

University of Maryland, Baltimore
PII-154 - PREDICTIVE MODELING OF TACROLIMUS DOSE REQUIREMENTS AND TRANSPLANTATION OUTCOME IN LUNG TRANSPLANT RECIPIENTS ON SYSTEMIC AZOLE ANTIFUNGALS
Pawan Gupta
Favorite
Gu, Shaopeng

University of South Dakota
PII-088 - RISK DETERMINANTS FOR DRUG-INDUCED LIVER INJURY WITH COMMON ANTIBIOTICS IN THE ALL OF US RESEARCH PROGRAM
Shaopeng Gu
Favorite
Gutierrez, Marcelo

Amylyx Pharmaceuticals, Inc.
LB-013 - EVALUATION OF SINGLE DOSE AND STEADY STATE PHARMACOKINETICS AND SAFETY OF AMX0035 IN CAUCASIAN AND JAPANESE HEALTHY MALE AND FEMALE PARTICIPANTS.
Marcelo Gutierrez
Favorite
H
Hagenauer, Mia

Cincinnati Children's Hospital Medical Center
PII-202 - HIGHER CLEARANCE WHILE ON HIGH-DOSE CONTINUOUS DIALYSIS IS ASSOCIATED WITH DECREASED TARGET ATTAINMENT OF PIPERACILLIN IN A PATIENT POST-KIDNEY TRANSPLANT FOR PRIMARY HYPEROXALURIA.
Mia Hagenauer
Favorite
Hai, Min

The Ohio State University
PII-141 - PILOT FEASIBILITY STUDY OF AN ORAL CYP3A4/2C19 PROBE COCKTAIL TO PREDICT BORTEZOMIB CLEARANCE IN MULTIPLE MYELOMA PATIENTS
Min Hai
Favorite
Ha, Na

Jeonbuk National University
PII-024 - STABILITY OF THE GUT MICROBIOME FROM HUMAN FECAL SAMPLES COLLECTED BY CONTACTLESS REGIONAL SHIPPING AND ITS APPLICATION IN CLINICAL TRIALS.
Na Ha
Favorite
Hartauer, Mattie

The University of North Carolina - Chapel Hill
LB-026 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR THE PREDICTION OF BCRP-MEDIATED DRUG INTERACTIONS USING R STATISTICAL SOFTWARE
Mattie Hartauer
Favorite
Hasan, Khaled

University of Maryland Eastern Shore
PII-044 - KNOWLEDGE, ATTITUDES, AND AWARENESS TOWARD MARIJUANA USE AT HISTORICALLY BLACK UNIVERSITY
Khaled Hasan
Favorite
Hines, Jacobi

University of Chicago Medical Center
PT-023 - EFFECT OF STEROID SPARING IMMUNOSUPPRESSIVE AGENTS USED IN THE TREATMENT OF IMMUNE RELATED ADVERSE EVENTS ON TUMOR OUTCOMES IN MELANOMA AND NON-SMALL CELL LUNG CANCER
Jacobi Hines
Favorite
Hogan, Janita

Merck & Co., Inc.
PII-013 - OPTIMIZATION OF PARKINSON'S DISEASE DIGITAL BIOMARKERS THROUGH CLINICAL TRIAL SIMULATIONS.
Janita Hogan
Favorite
Holland, Bryan

Certara UK
LB-004 - A NOVEL PHYSIOLOGICALLY BASED OCULAR PHARMACOKINETIC MODEL INCORPORATING ACCURATE DYNAMICS OF THE ANTERIOR EYE
Bryan Holland
Favorite
Huang, Zhong

The University of Chicago Pritzker School of Medicine
OAII-004 - CARE TEAM ATTRIBUTES PREDICT LIKELIHOOD OF UTILIZING PHARMACOGENOMIC INFORMATION.
Zhong Huang
Favorite
PT-013 - CARE TEAM ATTRIBUTES PREDICT LIKELIHOOD OF UTILIZING PHARMACOGENOMIC INFORMATION.
Zhong Huang
Favorite
Hunt, Porter

University of Utah
PT-011 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING WITH PAIRED PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF LEVETIRACETAM IN PATIENTS WITH EXTERNAL VENTRICULAR DRAINS.
Porter Hunt
Favorite
I
Irie, Kei

Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center
AI-007 - MACHINE LEARNING MODELING TO PREDICT INFLIXIMAB PHARMACOKINETICS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE
Kei Irie
Favorite
LB-017 - MACHINE LEARNING MODELING TO PREDICT INFLIXIMAB PHARMACOKINETICS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE
Kei Irie
Favorite
Ishibai, Mitsuru

Oita University
PII-193 - THE CONTENTS OF IMMUNOGENICITY ASSESSMENT DURING THE REVIEW PROCESS OF NEW DRUG APPLICATION IN JAPAN
Mitsuru Ishibai
Favorite
Ishihara, Yugo

Oita University
PII-209 - MEDICAL SUPPLY TRANSPORT TO EVACUATION SHELTERS BY DRONE: PROPOSAL OF OITA MODEL USING RENDEZVOUS POINTS OF AIR AMBULANCE.
Yugo Ishihara
Favorite
Ivaturri, Vijay

University of Maryland School of Pharmacy
AI-008 - PHARMACOKINETIC MODEL-GUIDED ENOXAPARIN DOSING IN THE NICU: RETROSPECTIVE ANALYSIS TO PLAN FOR PROSPECTIVE FEASIBILITY TRIAL.
Vijay Ivaturri
Favorite
J
Jafari, Eissa

College of Pharmacy, University of Florida
PII-224 - PREDICTORS OF ALZHEIMER'S DISEASE AND RELATED DEMENTIA (ADRD) IN A HYPERTENSION (HTN) POPULATION WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.
Eissa Jafari
Favorite
Jayanti, Rannissa Puspita

Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine
LB-030 - POPULATION PHARMACOKINETICS MODEL OF PYRAZINAMIDE TO OPTIMIZE TUBERCULOSIS TREATMENT: AN INTERETHNIC COHORT STUDY OF DIABETES MELLITUS EFFECT ON DRUG EXPOSURE.
Rannissa Puspita Jayanti
Favorite
TIP-005 - POPULATION PHARMACOKINETICS OF LEVOFLOXACIN IN KOREAN AND INDONESIAN TUBERCULOSIS PATIENTS: THE INFLUENCE OF RENAL FUNCTION AND DIABETES MELLITUS ON CLEARANCE.
Rannissa Puspita Jayanti
Favorite
Jennaro, Teddy

AbbVie
PII-049 - CLINICAL PHARMACOKINETICS OF ABBV-400, A NOVEL C-MET-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS.
Teddy Jennaro
Favorite
Johnson, Jordon

Arcus Biosciences Inc.
LB-015 - FOOD AND CO-ADMINISTRATION OF ACID REDUCING AGENTS (ARAS) HAVE NO CLINICALLY SIGNIFICANT EFFECT ON THE PHARMACOKINETICS OF ETRUMADENANT - A POPULATION PHARMACOKINETIC (POPPK) AND PHYSIOLOGICALLY-BASED MODELING EXPLORATION.
Jordon Johnson
Favorite
Jones, Austin

University of Virginia
PII-040 - THE IMPACT OF HIV-1 TAT AND MORPHINE ON SPATIAL DISTRIBUTION OF DRUGS IN THE BRAIN.
Austin Jones
Favorite
Jony, Md

Inje University, College of Medicine
LB-014 - EXTRAPOLATING TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION BETWEEN REMDESIVIR AND CLOFAZIMINE FROM IN VITRO TO IN VIVO: A STATIC APPROACH
Md Jony
Favorite
K
Kang, Sanghoon

University of Florida College of Pharmacy Department of Pharmaceutics
PII-184 - TOWARDS ASSISTING POTENTIAL PREVENTION CLINICAL TRIALS OF BONE-PROTECTIVE THERAPIES FOR DUCHENNE MUSCULAR DYSTROPHY USING DEEP SEGMENTED IMAGING BIOMARKER
Sanghoon Kang
Favorite
Kardouh, Miramar

The University of North Carolina at Chapel Hill and Certara
OAI-002 - UTILIZING A MINIMAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC (MPBPK) MODEL FOR PREDICTING MATERNAL AND FETAL EXPOSURE TO MONOCLONAL ANTIBODIES DURING PREGNANCY
Miramar Kardouh
Favorite
PT-001 - UTILIZING A MINIMAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC (MPBPK) MODEL FOR PREDICTING MATERNAL AND FETAL EXPOSURE TO MONOCLONAL ANTIBODIES DURING PREGNANCY
Miramar Kardouh
Favorite
Karelina, Tatiana

InSysBio CY
PII-220 - RESPONSE TO LYMPHOCYTE DEPLETING AND LYMPHOCYTE MODULATING THERAPIES IN DIFFERENT POPULATIONS OF PATIENTS WITH MULTIPLE SCLEROSIS INVESTIGATED BY QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL
Tatiana Karelina
Favorite
Kawaguchi, Atsuhiro

Mitsubishi Tanabe Pharma Co
PII-133 - PHARMACOKINETICS OF EDARAVONE - COMPARISON OF EXPOSURE BETWEEN JAPANESE AND NON-JAPANESE BY POPULATION PHARMACOKINETIC ANALYSIS.
Atsuhiro Kawaguchi
Favorite
Keshavarz, Ali

Amylyx Pharmaceuticals, Inc.
LB-005 - A PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF AMX0035 IN PARTICIPANTS WITH AMYOTROPHIC LATERAL SCLEROSIS
Ali Keshavarz
Favorite
Kiesel, Brian

Bristol Myers Squibb
PII-145 - POPULATION PHARMACOKINETIC MODELING OF ALNUCTAMAB, A BCMA-BINDING T CELL ENGAGER, TO CHARACTERIZE THE BIOAVAILABILITY AND PHARMACOKINETICS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
Brian Kiesel
Favorite
Killam, Shayna

University of Montana
CT-003 - PERSPECTIVES ON PHARMACOGENETIC-GUIDED TOBACCO CESSATION IN AN AMERICAN INDIAN POPULATION
Shayna Killam
Favorite
PII-205 - PERSPECTIVES ON PHARMACOGENETIC-GUIDED TOBACCO CESSATION IN AN AMERICAN INDIAN POPULATION
Shayna Killam
Favorite
Kim, Heungjo

Department of Pharmaceutical Medicine and Regulatory Science, Yonsei University
LB-018 - MODEL BASED META ANALYSIS OF IMATINIB PHARMACOKINETICS: IN ABCB1, ABCG2, AND CYP3A5 GENOTYPES.
Heungjo Kim
Favorite
Kim, Jae Hoon

Chungnam National University
E-001 - INVESTIGATION OF THE RELATIONSHIP BETWEEN LEPR GENOTYPE-LEPTIN-GUT MICROBIOTA COMPOSITION IN HEALTHY NON-OBESE KOREAN ADULTS.
Jae Hoon Kim
Favorite
Kim, Se Jin

SUNY at Buffalo
PII-002 - DEVELOPMENT OF A TRANSLATION PK-PD MODEL FOR IN VIVO CAR-T CELL THERAPIES USING CAR MRNA LOADED POLYMERIC NANOPARTICLE VECTOR
Se Jin Kim
Favorite
Kim, So-Yeon

Jeonbuk National University
CT-010 - COMPARATIVE PHARMACOKINETICS AND SAFETY OF DWJ1451 AND CO-ADMINISTRATION OF OLMESARTAN MEDOXOMIL/AMLODIPINE/ROSUVASTATIN AND EZETIMIBE TABLETS IN HEALTHY KOREAN SUBJECTS
So-Yeon Kim
Favorite
PII-106 - COMPARATIVE PHARMACOKINETICS AND SAFETY OF DWJ1451 AND CO-ADMINISTRATION OF OLMESARTAN MEDOXOMIL/AMLODIPINE/ROSUVASTATIN AND EZETIMIBE TABLETS IN HEALTHY KOREAN SUBJECTS
So-Yeon Kim
Favorite
Kotsybar, Joseph

U.S. Food and Drug Administration
PII-190 - GLOBAL HARMONIZATION OF IMMEDIATE-RELEASE SOLID ORAL DRUG PRODUCT BIOEQUIVALENCE RECOMMENDATIONS AND THE IMPACT ON GENERIC DRUG DEVELOPMENT.
Joseph Kotsybar
Favorite
Kowalski, Karey

Pfizer, Inc.
PII-100 - BOSUTINIB MODEL-INFORMED PEDIATRIC DOSE RECOMMENDATIONS FOR LABEL SIMPLIFICATION
Karey Kowalski
Favorite
Kuo-Esser, Lance

University of California, San Francisco
PII-036 - EFAVIRENZ AND DOLUTEGRAVIR MAY ALTER SIROLIMUS METABOLISM IN PEOPLE WITH HIV
Lance Kuo-Esser
Favorite
Kyler, Kathryn

Children's Mercy Kansas City
PII-175 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR PANTOPRAZOLE IN CHILDREN WITH OBESITY.
Kathryn Kyler
Favorite
L
Lam, Inez

Johns Hopkins University
PT-022 - COMPUTATIONAL SYSTEMS PHARMACOLOGY OF PYRROLOBENZODIAZEPINE-BASED ANTIBODY-DRUG CONJUGATES
Inez Lam
Favorite
Lam, Kevin

Thomas Jefferson University
PII-129 - ONDANSETRON FOR THE TREATMENT OF NEONATAL OPIOID WITHDRAWAL SYNDROME.
Kevin Lam
Favorite
Larson, Kajal

Innoviva Specialty Therapeutics, Inc
PII-035 - A BIOEQUIVALENCE AND FOOD EFFECT CLINICAL STUDY OF ZOLIFLODACIN, FIRST-IN-CLASS ORAL ANTIBIOTIC, BEING DEVELOPED FOR THE TREATMENT OF UNCOMPLICATED GONORRHEA
Kajal Larson
Favorite
Le, Anh-Dung

U.S. Food and Drug Administration
PII-001 - APPROVED THERAPEUTIC PROTEINS WITH CHALLENGES IN CLINICAL ENDPOINTS EVALUATION WHERE PHARMACODYNAMIC BIOMARKERS MAY IMPROVE EFFICIENCY OF BIOSIMILAR DEVELOPMENT
Anh-Dung Le
Favorite
Lee, Hyoeun

Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital
PII-131 - PHARMACOKINETIC PARAMETER ESTIMATION OF GENTAMICIN IN AN OBESE HEMODIALYSIS PATIENT: A CASE REPORT
Hyoeun Lee
Favorite
Lee, Sooyoun

Seoul National University Hospital
PII-107 - COMPARATIVE PHARMACOKINETICS/PHARMACODYNAMICS OF FIXED-DOSE COMBINATION OF RABEPRAZOLE/MAGNESIUM OXIDE 10/350MG (DHNP-2001A) TO THE CONVENTIONAL ENTERIC-COATED RABEPRAZOLE 10MG
Sooyoun Lee
Favorite
Lee, Sujong

Seoul National University Hospital
PII-114 - EVALUATION OF HIGH-DOSE VUTIGLABRIDIN IN HEALTHY PARTICIPANTS: SAFETY, FOOD EFFECT, AND PHARMACOKINETICS AFTER SINGLE AND MULTIPLE ORAL ADMINISTRATIONS
Sujong Lee
Favorite
Lee, Yunghon

U.S. Food and Drug Administration
PII-006 - A SNAPSHOT OF PHARMACODYNAMIC BIOMARKERS BIOANALYSIS IN 16 BLAS APPROVED FOR NEUROLOGY INDICATIONS.
Yunghon Lee
Favorite
Lennox, Ashley

Geron Corporation
PII-050 - CLINICAL PHARMACOLOGY OF IMETELSTAT, A FIRST-IN-CLASS OLIGONUCLEOTIDE TELOMERASE INHIBITOR
Ashley Lennox
Favorite
PII-128 - NOVEL NONLINEAR POPULATION PHARMACOKINETIC MODEL OF IMETELSTAT, A FIRST-IN-CLASS OLIGONUCLEOTIDE TELOMERASE INHIBITOR
Ashley Lennox
Favorite
Leonov, Vladislav

INSYSBIO UK Ltd, Edinburgh, UK
PII-014 - UNRAVELING IL9 SERUM DISTRIBUTION PATTERNS: INSIGHTS FROM THE CYTOCON DATABASE
Vladislav Leonov
Favorite
Lewis, Tamorah

The University of Toronto Temerty Faculty of Medicine
LB-024 - PHARMACOKINETIC MODEL-GUIDED ENOXAPARIN DOSING IN THE NICU: RETROSPECTIVE ANALYSIS TO PLAN FOR PROSPECTIVE FEASIBILITY TRIAL.
Tamorah Lewis
Favorite
Liao, Michael

Genentech
CT-011 - ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)
Michael Liao
Favorite
PII-052 - ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)
Michael Liao
Favorite
Li, Chao

AnHeart Therapeutics
PII-153 - PREDICTION OF PFS BASED ON TUMOR GROWTH INHIBITION METRICS IN HER2 POSITIVE BREAST CANCER PATIENTS FOLLOWING HER2 ADC FS-1502 TREATMENT
Chao Li
Favorite
Lindsey, Jacob

Purdue University
PII-172 - IN SILICO PREDICTION OF ION CHANNEL EFFECTS OF METHADONE LEADING TO QT INTERVAL PROLONGATION.
Jacob Lindsey
Favorite
Li, Tommy

Genmab
PII-003 - EVALUATION OF DRUG-DRUG INTERACTION (DDI) POTENTIAL FOLLOWING EPCORITAMAB TREATMENT: RESULTS FROM EXPANSION OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL.
Tommy Li
Favorite
PII-004 - MODEL-BASED REPRIMING WINDOW SELECTION FOR SUBCUTANEOUS EPCORITAMAB.
Tommy Li
Favorite
Littleton, Shana

University of Michigan - Ann Arbor
CT-009 - ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY
Shana Littleton
Favorite
PII-073 - ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY
Shana Littleton
Favorite
Liu, Guansheng

US FDA
LB-023 - PATH TO REGULATORY REVIEW OF A QUANTITATIVE SYSTEM PHARMACOLOGY (QSP) MODEL
Guansheng Liu
Favorite
Liu, Jing

Pfizer, Inc.
PII-194 - A PHASE 1 STUDY COMPARING PHARMACOKINETICS OF RIMEGEPANT 25 MG ORALLY DISINTEGRATING TABLET (ODT) PEDIATRIC FORMULATION WITH RIMEGEPANT 75 MG ODT ADULT FORMULATION, WHEN ADMINISTERED AT A SINGLE DOSE OF 75 MG UNDER FASTING CONDITIONS
Jing Liu
Favorite
Liu, Shuhan

University of Michigan
PII-059 - MODELING M-PROTEIN DYNAMICS IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING VENETOCLAX: UTILITY OF EARLY M-PROTEIN MONITORING TO PREDICT PROGRESSION FREE SURVIVAL
Shuhan Liu
Favorite
Liu, Xiaomei

Children's National Medical Center
PII-206 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR PREGNANCY.
Xiaomei Liu
Favorite
Li, Xinnong

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
PII-168 - DEVELOPMENT OF GRAPHICAL INTERFACE IN R SHINY FOR PBPK MODEL-BASED PREDICTION AND SIMULATION OF DRUG DELIVERY IN THE FEMALE REPRODUCTIVE TRACT
Xinnong Li
Favorite
PT-014 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF DRUG DELIVERY IN THE FEMALE REPRODUCTIVE TRACT
Xinnong Li
Favorite
Lovern, Mark

InSilicoTrials Technologies LLC, Stafford, USA
LB-029 - POPULATION PHARMACOKINETICS (PK) AND PHARMACODYNAMIC (PD) ANALYSES OF MULTIPLE INTRAVENOUS INFUSIONS OF NX210C PEPTIDE IN HEALTHY ELDERLY VOLUNTEERS (HEVS)
Mark Lovern
Favorite
M
Madia, Priyanka

Regeneron Pharmaceuticals, Inc.
PII-054 - EVALUATION OF PHARMACOKINETICS (PK), SERUM CYTOKINES, AND SAFETY FOLLOWING INTRAVENOUS (IV) OR SUBCUTANEOUS (SC) STEP-UP DOSING OF UBAMATAMAB, A MUC16XCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RECURRENT OVARIAN CANCER (OC)
Priyanka Madia
Favorite
Mahadevan, Ramya

USC Alfred E Mann school of pharmacy
LB-002 - A MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC (MPBPK) MODEL TO CHARACTERIZE PSA07 BACTERIOPHAGE (PHAGE) PHARMACOKINETICS (PK) FOLLOWING INTRAVENOUS (IV) ADMINISTRATION IN MICE FOR TREATMENT OF P. AERUGINOSA (PSA) INFECTIONS
Ramya Mahadevan
Favorite
Marathe, Anshu

Novartis Biomedical Research, East Hanover, USA
LB-020 - MODEL-INFORMED DRUG DEVELOPMENT APPROACH FOR APPROVAL OF INTRAVENOUS FORMULATION OF SECUKINUMAB IN PSORIATIC ARTHRITIS (PSA), ANKYLOSING SPONDYLITIS (AS) AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)
Anshu Marathe
Favorite
Marrero-Polanco, Jean

Mayo Clinic
AI-005 - PREDICTING REMISSION IN ACUTE BIPOLAR DEPRESSION: A MACHINE LEARNING STUDY WITH CROSS-TRIAL REPLICATION
Jean Marrero-Polanco
Favorite
PT-009 - PREDICTING REMISSION IN ACUTE BIPOLAR DEPRESSION: A MACHINE LEARNING STUDY WITH CROSS-TRIAL REPLICATION
Jean Marrero-Polanco
Favorite
Martin, James

University of Colorado Anschutz Medical Campus
PII-082 - PERSPECTIVES ABOUT THE DEVELOPMENT AND IMPLEMENTATION OF PHARMACOGENOMIC CLINICAL DECISION SUPPORT TOOLS IN RURAL AND UNDERSERVED COMMUNITIES
James Martin
Favorite
Masinde, Sheila

Regeneron Pharmaceuticals, Inc.
PII-060 - PHARMACOKINETICS (PK) AND SOLUBLE MET (SMET) PHARMACODYNAMICS (PD) OF REGN5093, A MET X MET BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)
Sheila Masinde
Favorite
Matsumoto, Natsumi

Showa University
PII-068 - REDUCED SYSTEMIC EXPOSURE TO A CAPECITABINE METABOLITE 5'-DFUR IN ABCC4 POLYMORPHISM MAY BE ASSOCIATED WITH INCREASES IN CAMP LEVEL AND SUBSEQUENT UPREGULATION OF THYMIDINE PHOSPHORYLASE
Natsumi Matsumoto
Favorite
McComb, Mason

Amgen
PII-120 - IMPACT OF MODERATE OR SEVERE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SOTORASIB AND ITS METABOLITES
Mason McComb
Favorite
McGirr, Kimiko

Applied BioMath
PII-211 - A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR PRECLINICAL TO CLINICAL TRANSLATION OF ANTIBODY-DRUG CONJUGATE (ADC) EFFICACY AND THROMBOCYTOPENIA.
Kimiko McGirr
Favorite
Mehanna, Mai

U.S. Food and Drug Administration
PII-015 - UTILITY OF MIROMICS AND INTEGRATIVE MULTI-OMICS SYSTEMS ANALYSIS FOR IDENTIFICATION OF MIRNAS AS POTENTIAL PHARMACODYNAMIC BIOMARKERS OF IFNβ-1A BIOLOGICS
Mai Mehanna
Favorite
Merali, Samira

Bristol Myers Squibb
PII-102 - CLINICAL DRUG-DRUG INTERACTION STUDY INTEGRATED WITH PBPK MODELLING PROVIDES INSIGHTS INTO THE INDUCTION POTENTIAL OF MAVACAMTEN ACROSS CYP2C19 PHENOTYPES.
Samira Merali
Favorite
Mian, Paola

Clinical Pharmacy and Pharmacology
PII-135 - PHARMACOKINETICS OF MONOCLONAL ANTIBODIES THROUGHOUT PREGNANCY: A SYSTEMATIC LITERATURE REVIEW
Paola Mian
Favorite
PII-199 - DESIGN AND MECHANICS OF FIVE MAJOR HUMAN MILK DRUG RESEARCH BIOBANKS: TIME TO CROSS BORDERS AND BARRIERS
Paola Mian
Favorite
Michaud, Veronique

GalenusRx Inc.
PII-010 - EVALUATION OF PLASMA BIOMARKERS TO ASSESS THEIR ABILITY TO PREDICT CYP2D6 ACTIVITY IN INDIVIDUALS INCLUDING PATIENTS WITH TYPE 2 DIABETES.
Veronique Michaud
Favorite
Miles, Nick

AbbVie
PII-137 - PHARMACOKINETICS, SAFETY AND TOLERABILITY OF ABBV-552 IN HEALTHY ADULT JAPANESE AND HAN CHINESE SUBJECTS
Nick Miles
Favorite
Miller, Emily

VCU School of Pharmacy
PT-012 - THE EFFECT OF BUPRENORPHINE VERSUS METHADONE TREATMENT ON NEUROCOGNITIVE IMPAIRMENT IN PERSONS WITH HIV AND OPIOID USE DISORDER.
Emily Miller
Favorite
Mina, Mirette

U.S. Food and Drug Administration
PII-188 - DEEP DIVE INTO GENERIC DRUG APPLICATIONS TO SEEK DATA-DRIVEN HARMONIZATION OF BIOEQUIVALENCE CRITERIA FOR NARROW THERAPEUTIC INDEX DRUGS.
Mirette Mina
Favorite
Miyata, Koji

Department of Clinical Pharmacology and Therapeutics, University of Tokushima Graduate School of Biomedical Sciences
PII-181 - FLUOROQUINOLONES ATTRIBUTE AORTIC DISEASES THROUGH ENDOTHELIAL DYSFUNCTION.
Koji Miyata
Favorite
Mizuno, Kana

Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center
E-002 - MODEL-INFORMED PRECISION DOSING GUIDANCE OF ETHOSUXIMIDE DEVELOPED FROM A RANDOMIZED CONTROLLED CLINICAL TRIAL OF CHIILDHOOD ABSENCE EPILEPSY.
Kana Mizuno
Favorite
E-002 - MODEL-INFORMED PRECISION DOSING GUIDANCE OF ETHOSUXIMIDE DEVELOPED FROM A RANDOMIZED CONTROLLED CLINICAL TRIAL OF CHIILDHOOD ABSENCE EPILEPSY.
Kana Mizuno
Favorite
Montalvo, Abelardo

University of Florida College of Pharmacy
PII-086 - RACIAL DIFFERENCES IN THE ASSOCIATION BETWEEN UGT1A1*28 AND GENE EXPRESSION OF UGT1A1 AND SEARCHING FOR NOVEL REGULATORY VARIANTS OF UGT1A1.
Abelardo Montalvo
Favorite
Morales Junior, Ronaldo

Hospital Sírio-Libanês
CT-004 - PIPERACILIN PHARMACOKINETICS AND TARGET ATTAINMENT IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS.
Ronaldo Morales Junior
Favorite
PII-207 - PIPERACILIN PHARMACOKINETICS AND TARGET ATTAINMENT IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS.
Ronaldo Morales Junior
Favorite
Moye, Matthew

Merck & Co., Inc.
PII-025 - ASCENDING DOSE IN VIVO QT STUDIES HAVE THE SENSITIVITY TO DETECT QT INTERVAL CHANGES THAT ARE SUFFICIENT TO SUPPORT A CLINICAL QT WAIVER: ASSESSMENT OF QT/QTC INTERVAL CHANGES USING AN ESCALATING DOSE DESIGN IN TELEMETERED BEAGLE DOGS.
Matthew Moye
Favorite
Muehlebach, Molly

University of Nebraska Medical Center
PII-069 - THE ANTI-OSTEOCLASTIC EFFECTS AND BONE-AFFINITY PROPERTIES OF GERANYLGERANYL DIPHOSPHATE SYNTHASE INHIBITOR RAM2061
Molly Muehlebach
Favorite
Musatova, Veronika

INSYSBIO CY Ltd, Limassol, Cyprus
PII-221 - TETRAVALENCY IMPACT ON BISPECIFIC ANTIBODY-ACHIEVED RECEPTOR OCCUPANCY AND TARGET DOWNREGULATION: ESTIMATION BY TRANSLATIONAL PK/RO MODEL OF CTX8371 ANTIBODY
Veronika Musatova
Favorite
N
Nahid, Noor

Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, University of Florida College of Pharmacy
PII-080 - IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
Noor Nahid
Favorite
PT-017 - IMPACT OF CYP2D6 INHIBITORS ON PAIN CONTROL BY THE OPIOIDS
Noor Nahid
Favorite
Na, Joo Young

The Ohio State University
PII-127 - MODELING AND SIMULATION TO EXPLORE MECHANISMS OF PHARMACOKINETIC DRUG-DRUG INTERACTIONS OF ABEMACICLIB AND OLAPARIB IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OVARIAN CANCER
Joo Young Na
Favorite
Neal, Reem

UT Southwestern Medical Center
LB-006 - ARTERIAL STIFFNESS AND SYSTEMIC VASCULAR CORRELATES OF BRAIN AMYLOIDOSIS AND PRECLINICAL AD
Reem Neal
Favorite
Nepal, Mahesh

The Ohio State University
PII-041 - A CHEMICAL BIOLOGY STRATEGY FOR PREDICTING OATP1B-TYPE TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION (DDI) LIABILITIES
Mahesh Nepal
Favorite
Nguyen, Duyen

Division of Therapeutic Performance II, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
PII-187 - ASSESSMENT OF MALE INFERTILITY RISKS TO SUPPORT PRODUCT-SPECIFIC GUIDANCE DEVELOPMENT FOR GENERIC ORAL PRODUCTS.
Duyen Nguyen
Favorite
Nguyen, Van

BioPharma Services Inc.
E-003 - UNLOCKING THE DATA MYSTERY: A SIMULATION BASED DECISION GUIDE TO EVALUATE MISSING DATA IN BIOAVAILABILITY AND BIOEQUIVALENCE STUDIES.
Van Nguyen
Favorite
Niimura, Takahiro

Tokushima University
PII-189 - EVALUATION OF CARDIOVASCULAR TOXICITY PROFILE OF ALK INHIBITORS USING ADVERSE EVENT REPORTING DATABASE
Takahiro Niimura
Favorite
Niloy, Kumar Kulldeep

St. Jude Children's Research Hospital, The University of Tennessee Health Science Center
LB-027 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO PREDICT HUMAN DOSE OF MITHRAMYCIN ANALOGUE FOR THE TREATMENT OF EWING SARCOMA
Kumar Kulldeep Niloy
Favorite
LB-028 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO SUPPORT PEDIATRIC DOSING OF OLVEREMBATINIB IN CHILDREN WITH RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Kumar Kulldeep Niloy
Favorite
Nishii, Rina

Bristol Myers Squibb
PII-016 - CELLULAR KINETICS OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, LISOCABTAGENE MARALEUCEL (LISO-CEL) AND ITS ASSOCIATION WITH EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Rina Nishii
Favorite
Noorani, behnam

AbbVie, Inc., Chicago, Illinois, USA
PII-061 - PHARMACOKINETICS (PK) OF MIRZOTAMAB CLEZUTOCLAX (MIRZO-C) IN PATIENTS WITH RELAPSED AND REFRACTORY SOLID TUMORS: FIRST IN HUMAN STUDY RESULTS
behnam Noorani
Favorite
Norris, Madeline

University of Florida
PII-085 - POTENTIAL HEALTHCARE DISPARITIES AMONG PATIENTS WHO REGISTER FOR NOVEL PHARMACOGENETICS CONSULTATION SERVICE
Madeline Norris
Favorite
O
O'Kane, Aislinn

Indiana University School of Medicine
PII-174 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO ASSESS THE IMPACT OF GENETIC VARIABILITY IN PATIENTS RECEIVING DEXMEDETOMIDINE.
Aislinn O'Kane
Favorite
Olivares-Morales, Andrés

Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd
PII-166 - DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR BALOVAPTAN AND ITS MAJOR METABOLITE TO EVALUATE THEIR CYP3A4-MEDIATED VICTIM DRUG-DRUG INTERACTION (DDI) LIABILITY
Andrés Olivares-Morales
Favorite
Osei, Wilberforce

Purdue University College of Pharmacy, , Indiana University School of Medicine
PII-077 - EVALUATING THE ACCURACY OF PHARMACOGENOTYPE EXTRACTION FROM SOMATIC WHOLE EXOME SEQUENCING
Wilberforce Osei
Favorite
P
Paglialunga, Sabina

Celerion
PII-028 - NO PHOTOTOXICITY OR PHOTOALLERGY EFFECT WITH MRX-5LBT (10%) LIDOCAINE PATCH ADMINISTRATION
Sabina Paglialunga
Favorite
PII-032 - WHAT TO EXPECT FROM A PHENYTOIN DRUG-DRUG INTERACTION STUDY: ADVERSE EVENT PROFILING AND SAFETY ASSESSMENT
Sabina Paglialunga
Favorite
Paice, Kelli

Cincinnati Children's Hospital Medical Center
PII-112 - EARLY MEROPENEM PHARMACOKINETICS AND TARGET ATTAINMENT IN CHILDREN WITH SEVERE VS NON-SEVERE SEPSIS
Kelli Paice
Favorite
Paleja, Bhairav

Vantage Research
PII-018 - CLINICAL DOSE PREDICTION FOR CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPIES USING A MULTI-SCALE QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) PLATFORM MODEL
Bhairav Paleja
Favorite
Pan, Xian

Certara, Simcyp
PII-167 - DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR VENLAFAXINE AND O-DESMETHYLVENLAFAXINE: ASSESSING THE IMPACT OF CYP2D6, CYP2C9 AND CYP2C19 GENETIC POLYMORPHISMS
Xian Pan
Favorite
PII-170 - EXPOSURE OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE IN LACTATING MOTHERS AND THEIR INFANTS: INSIGHTS FROM A PBPK MODEL
Xian Pan
Favorite
Park, Hyunseo

Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Sciences Center
PII-214 - DEVELOPMENT OF A MECHANISTIC CK-PD MODEL TO QUANTITATIVELY CHARACTERIZE A CD19 DIRECTED CAR-T CELL THERAPY PRODUCT DEVELOPED USING RAPID MANUFACTURING
Hyunseo Park
Favorite
PT-016 - DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Hyunseo Park
Favorite
PWII-004 - DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Hyunseo Park
Favorite
Parrott, Neil

F Hoffmann LaRoche
PII-169 - EVALUATION OF THE POTENTIAL IMPACT ON PHAMACOKINETICS OF VARIOUS CYTOCHROME P450 SUBSTRATES OF INCREASING IL-6 LEVELS FOLLOWING ADMINISTRATION OF THE T-CELL BISPECIFIC ENGAGER GLOFITAMAB
Neil Parrott
Favorite
Pavia, Kathryn

Cincinnati Children's Hospital Medical Center
PII-204 - NEUROLOGIC CONCERNS IN CRITICALLY ILL CHILDREN RECEIVING CEFEPIME
Kathryn Pavia
Favorite
Piscitelli, Joseph

Pfizer, Inc.
PII-046 - AN EVALUATION OF THE DRUG INTERACTION POTENTIAL OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN PATIENTS WITH BRAF V600-MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS
Joseph Piscitelli
Favorite
Polepally, Akshanth

Abbvie Inc.
PII-065 - POPULATION PHARMACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
Akshanth Polepally
Favorite
Popescu, Vlad

Mayo Clinic
PII-197 - CLINICAL EFFECTS OF MEDICAL CANNABIS FOR POST-TRAUMATIC STRESS DISORDER (PTSD) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS - A RETROSPECTIVE COHORT STUDY BASED ON MINNESOTA'S MEDICAL CANNABIS REGISTRY.
Vlad Popescu
Favorite
Powell, Nick

Indiana University School of Medicine, Division of Clinical Pharmacology
PII-078 - EVALUATION OF G6PD ACTIVITY IN ALL OF US
Nick Powell
Favorite
Power-Hays, Alexandra

Cincinnati Children's Hospital, Division of Hematology
PII-034 - THE FEASIBILITY OF PHARMACOKINETIC-GUIDED HYDROXYUREA DOSING FOR CHILDREN WITH SICKLE CELL ANEMIA IN UGANDA: ANALYSIS OF THE ALTERNATIVE DOSING AND PREVENTION OF TRANSFUSIONS (ADAPT) TRIAL.
Alexandra Power-Hays
Favorite
Punwani, Naresh

Incyte Research Institute
PII-092 - A PHASE 1 SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECTS AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099318 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS
Naresh Punwani
Favorite
PII-094 - A PHASE 1, SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECT AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099280 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS
Naresh Punwani
Favorite
Q
Qian, Lixuan

City University of New York
LB-007 - ASSESSING POTENTIAL DRUG-DRUG INTERACTIONS INVOLVING Δ-9-TETRAHYDROCANNABINOL AND CANNABIDIOL IN HEALTHY ADULTS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS
Lixuan Qian
Favorite
Qian, Yuli

AbbVie Inc.
PII-012 - LEVERAGING COPROPORPHYRIN-I AS AN ENDOGENOUS OATP1B BIOMARKER TO DISENTANGLE THE EFFECTS OF CEDIROGANT IN COMPLEX DRUG-DRUG INTERACTIONS.
Yuli Qian
Favorite
PII-118 - EXTRAPOLATION APPROACH FOR UPADACITINIB IN JUVENILE IDIOPATHIC ARTHRITIS LEVERAGING PHARMACOKINETICS, EXPOSURE-RESPONSE, AND REAL-WORLD PATIENT DATA.
Yuli Qian
Favorite
Qiu, Xiao

University of Georgia
LB-036 - UNDERSTANDING RELAXIN MECHANISMS OF ACTION THROUGH CARDIORENAL SYSTEMS PHARMACOLOGY MODELING
Xiao Qiu
Favorite
R
Radice, Casey

Merck
PII-104 - CLINICAL TRIAL SIMULATIONS FOR OPTIMAL SAMPLING TO ASSESS DURABILITY OF PCV IMMUNE RESPONSE IN ADULTS.
Casey Radice
Favorite
Radwan, Alaa

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado|Anschutz Medical Campus
OAII-001 - EVALUATION OF PHARMACOGENOMIC MEDICATION PRESCRIBING PATTERNS IN RURAL VERSUS URBAN SETTINGS.
Alaa Radwan
Favorite
PII-076 - ESTIMATED PREVALENCE OF ACTIONABLE EXPOSURES TO PHARMACOGENETIC SUPPORTIVE CARE MEDICATIONS AMONG PATIENTS WITH GASTROINTESTINAL CANCERS.
Alaa Radwan
Favorite
PT-004 - EVALUATION OF PHARMACOGENOMIC MEDICATION PRESCRIBING PATTERNS IN RURAL VERSUS URBAN SETTINGS.
Alaa Radwan
Favorite
Ramesh, Shyam

University of Florida
PII-099 - AUTOSOMAL DOMINANT TUBULOINTERSTITIAL KIDNEY DISEASE: JOINT LONGITUDINAL-SURVIVAL DISEASE PROGRESSION MODELS.
Shyam Ramesh
Favorite
RATH, SEEPRARANI

Rutgers, the State University of New Jersey
PT-026 - CAN MODEL BASED APPROACHES ACCURATELY IDENTIFY BIO(IN)EQUIVALENCE OF TOPICAL CLOTRIMAZOLE PRODUCTS?
SEEPRARANI RATH
Favorite
Raviele, Anthony

Bristol Myers Squibb
PII-021 - EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL)
Anthony Raviele
Favorite
Remaily, Bryan

The Ohio State University
PII-011 - FC GAMMA RECEPTORS CONTRIBUTE TO CACHEXIA MEDIATED INCREASES IN MONOCLONAL ANTIBODY CLEARANCE
Bryan Remaily
Favorite
PT-018 - MINIMAL SAMPLING TO ASSESS MECHANISMS LINKING IMMUNE CHECKPOINT INHIBITOR PHARMACOKINETICS AND OUTCOMES IN CANCER PATIENTS
Bryan Remaily
Favorite
PWII-003 - MINIMAL SAMPLING TO ASSESS MECHANISMS LINKING IMMUNE CHECKPOINT INHIBITOR PHARMACOKINETICS AND OUTCOMES IN CANCER PATIENTS
Bryan Remaily
Favorite
Riselli, Andrew

University of California, San Francisco
TIP-001 - A CLINICAL STUDY OF NOVEL BCRP AND ESTABLISHED OATP BIOMARKERS FOR PREDICTING DRUG-DRUG INTERACTIONS.
Andrew Riselli
Favorite
Ryu, Kyongkuk

Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University
LB-031 - POPULATION PHARMACOKINETICS OF BORTEZOMIB: MODEL-BASED META-ANALYSIS
Kyongkuk Ryu
Favorite
S
Saleh, Ateka

Mayo Clinic
PT-002 - POST-TRANSCRIPTIONAL GENE REGULATION AND ANTIDEPRESSANT TREATMENT RESPONSE: FUNCTIONAL CHARACTERIZATION OF ELAVL2 RNA-BINDING PROTEIN IN IPSC-DERIVED NEURONS.
Ateka Saleh
Favorite
Sanga, Madhu

Janssen Research and Development LLC
PII-110 - DRUG-DRUG INTERACTION EFFECT OF STEADY STATE LAZERTINIB EXPOSURE ON THE SINGLE-DOSE PHARMACOKINETICS OF MIDAZOLAM, ROSUVASTATIN AND METFORMIN.
Madhu Sanga
Favorite
Schmith, Virginia (Ginny)

Schmith PK/PD Consulting LLC
PII-123 - METABOLIC PROFILING OF ECOPIPAM
Virginia (Ginny) Schmith
Favorite
PII-125 - MICRODOSING APPROACH TO EVALUATE WHETHER ECOPIPAM AFFECTS DRUG METABOLISM AND TRANSPORT OF CONCOMITANT MEDICATIONS
Virginia (Ginny) Schmith
Favorite
Seong, Hyeon-jeong

Inje University, College of Medicine
LB-012 - DEVELOPMENT OF LC-MS/MS METHOD FOR THE SIMULTANEOUS DETERMINATION OF ANTI-NONTUBERCULOUS MYCOBACTERIA PULMONARY DISEASE DRUGS IN HUMAN PLASMA
Hyeon-jeong Seong
Favorite
Shahin, Mohamed

Pfizer, Inc.
PII-108 - DEVELOPING A PEDIATRIC ORAL SUSPENSION FORMULATION OF ABROCITINIB: A RELATIVE BIOAVAILABILITY AND PALATABILITY ASSESSMENT STUDY IN ADULTS
Mohamed Shahin
Favorite
Sharma, Ankur

CSL Behring, King of Prussia, PA, USA
PII-142 - POPULATION EXPOSURE–RESPONSE ANALYSIS SUPPORTS EFFICACY OUTCOMES OF GARADACIMAB IN PATIENTS WITH HEREDITARY ANGIOEDEMA.
Ankur Sharma
Favorite
Shin, Maureen

University of California, San Francisco
PII-159 - THE NEED FOR EQUITABLE REPRESENTATION IN PHARMACOKINETIC STUDIES TO ENHANCE OPTIMAL DOSING STRATEGIES TO TREAT POVERTY-RELATED DISEASES IN MALNOURISHED CHILDREN.
Maureen Shin
Favorite
Shin, Wonsuk

CHA Bundang Medical Center
PII-091 - A PHASE 1 OPEN-LABEL, FIXED-SEQUENCE 3-PERIOD STUDY TO EVALUATE PHARMACOKINETIC INTERACTIONS BETWEEN FIMASARTAN AND INDAPAMIDE IN HEALTHY VOLUNTEERS
Wonsuk Shin
Favorite
Showel, Kelly

Mayo Clinic
PII-020 - EVIDENCE FOR INDUCIBLE CMV PROMOTER ACTIVITY IN HUMAN CHONDROCYTES
Kelly Showel
Favorite
Shugg, Tyler

Indiana University School of Medicine, Division of Clinical Pharmacology
PII-087 - REDUCTION OF NEXT-GENERATION SEQUENCING FILE SIZE FOR EFFICIENT PHARMACOGENOTYPE EXTRACTION.
Tyler Shugg
Favorite
So, Gerald

Indiana University
LB-009 - CANNABIDIOL INCREASES EXPOSURE OF TACROLIMUS IN HEALTHY VOLUNTEERS.
Gerald So
Favorite
PT-027 - INHIBITION OF TACROLIMUS METABOLISM BY CANNABIDIOL AND ITS METABOLITES IN VITRO.
Gerald So
Favorite
TIP-002 - DRUG-GENE-NUTRACEUTICAL INTERACTIONS OF CANNABIDIOL AND TACROLIMUS.
Gerald So
Favorite
Song, Jisoo

Seoul National University College of Medicine and Hospital
PII-155 - SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE INTRAVENOUS ADMINISTRATIONS OF LENZILUMAB IN HEALTHY KOREAN SUBJECTS
Jisoo Song
Favorite
Sperber, Nina

Durham VA Health Care System and Duke University Department of Population Health Sciences
PII-072 - A VALUE PROPOSITION FOR USING PHARMACOGENETIC TESTING IN MENTAL HEALTH CARE
Nina Sperber
Favorite
Stancil, Stephani

Children's Mercy Kansas City
PII-043 - ANTIDEPRESSANT EXPOSURE IN THE ADOLESCENT BRAIN: FLUOXETINE AND PHARMACOGENETIC INFLUENCES ON BRAIN DISPOSITION
Stephani Stancil
Favorite
Stern, Sydney

U.S. Food and Drug Administration
PII-180 - CLINICAL PHARMACOLOGY CONSIDERATIONS FOR FIRST-IN-HUMAN CLINICAL TRIALS FOR ENZYME REPLACEMENT THERAPY
Sydney Stern
Favorite
Stewart, Clinton

St. Jude Children's Research Hospital
LB-025 - PHARMACOKINETICALLY-GUIDED DOSING OF ORAL SORAFENIB IN PATIENTS WITH PEDIATRIC HEPATOCELLULAR CARCINOMA
Clinton Stewart
Favorite
Stocco, Gabriele

University of Trieste / Institute for Maternal and Child Health IRCCS Burlo Garofolo
PII-203 - KLEBSIELLA PNEUMONIAE CONTRIBUTES TO REDUCE THIOPURINES CYTOTOXICITY IN VITRO: POSSIBLE IMPLICATIONS OF BACTERIAL METABOLISM
Gabriele Stocco
Favorite
Storelli, Flavia

Pfizer
PII-070 - TUCATINIB DOES NOT INCREASE PACLITAXEL PLASMA CONCENTRATIONS IN PATIENTS WITH HER2+ GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Flavia Storelli
Favorite
Sun, Boguang

University of Minnesota College of Pharmacy
AI-002 - APPLICATION OF MACHINE LEARNING COMBINED WITH POPPK AND QSP MODELS FOR ADVERSE EVENTS RISK PREDICTION OF A CD19-TARGETING BISPECIFIC THERAPY
Boguang Sun
Favorite
PT-007 - APPLICATION OF MACHINE LEARNING COMBINED WITH POPPK AND QSP MODELS FOR ADVERSE EVENTS RISK PREDICTION OF A CD19-TARGETING BISPECIFIC THERAPY
Boguang Sun
Favorite
Sun, Wei-Jhe

Division Of Therapeutic Performance II, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
LB-001 - A GENERIC TACROLIMUS CAPSULE SHOWN NOT TO BE BIOEQUIVALENT TO THE BRAND TACROLIMUS CAPSULE IN A POST-APPROVAL PHARMACOKINETIC BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS
Wei-Jhe Sun
Favorite
Suram, Anitha

Blueprint Medicines Corporation
PII-173 - LEVERAGING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING AND CLINICAL DATA TO PREDICT DRUG-DRUG INTERACTIONS (DDI) OF AVAPRITINIB AND GUIDE DOSE ADJUSTMENTS.
Anitha Suram
Favorite
T
Tai, Hung-Liang

Ultragenyx Pharmaceutical
PII-182 - POPULATION PHARMACOKINETICS (PK) AND PK/PHARMACODYNAMICS ANALYSES TO REFINE PHASE 3 DOSE OF SETRUSUMAB IN PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA: RESULTS FROM PHASE 2 OF THE ORBIT STUDY
Hung-Liang Tai
Favorite
Tang, Fei

Genentech
LB-021 - MORPHINE-METABOLITE POPULATION PHARMACOKINETIC MODELING IN NEONATES WITH NEONATAL OPIOID WITHDRAWAL SYNDROME FOLLOWING ORAL ADMINISTRATION OF MORPHINE.
Fei Tang
Favorite
Tan, Mingliang
PII-185 - A QUANTITATIVE MODELING APPROACH TO PREDICT AVAILABILITY OF GENERIC ORPHAN DRUG PRODUCTS.
Mingliang Tan
Favorite
Tan, Wen Rui

Cincinnati Children Hospital Medical Center
LB-019 - MODEL-INFORMED DOSE OPTIMIZATION FOR PROPHYLACTIC PIPERACILLIN-TAZOBACTAM IN PERIOPERATIVE PEDIATRIC PATIENTS.
Wen Rui Tan
Favorite
Taylor, Zachary

Cincinnati Children's Hospital Medical Center
OAI-003 - UNDERSTANDING THE ASSOCIATIONS BETWEEN HIGH-DOSE METHOTREXATE PHARMACOKINETICS AND THE RISK OF TOXICITIES IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.
Zachary Taylor
Favorite
PII-071 - UNDERSTANDING THE ASSOCIATIONS BETWEEN HIGH-DOSE METHOTREXATE PHARMACOKINETICS AND THE RISK OF TOXICITIES IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.
Zachary Taylor
Favorite
Thiagarajan, Kannan

Vantage Research Inc
PII-215 - EVALUATING THE EFFICACY OF COMBINATION OF CHECKPOINT INHIBITORS AND CHEMOTHERAPY IN LUNG CANCER USING A MECHANISTIC MODEL
Kannan Thiagarajan
Favorite
Thompson, Corbin

Clinical Pharmacology Modeling and Simulation, Amgen
PII-063 - PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN ADULT PATIENTS WITH PREVIOUSLY TREATED SMALL CELL LUNG CANCER (SCLC)
Corbin Thompson
Favorite
Tiitto, Ville

University of California, San Francisco
PII-122 - INCREASED DOSE CORRECTED AUC FOLLOWING SLOW SUBCUTANEOUS, INTRAMUSCULAR AND ORAL VERSUS INTRAVENOUS BOLUS HUMAN DRUG DOSING AND ITS POTENTIAL FOR INCREASED DOSE CORRECTED PHARMACODYNAMIC EFFECTS.
Ville Tiitto
Favorite
Tippin, Tim

Chimerix, Inc.
PII-124 - METABOLISM AND DISPOSITION OF [14C]-ONC201 (DORDAVIPRONE) IN HEALTHY ADULT PARTICIPANTS
Tim Tippin
Favorite
PII-164 - ASSESSING CYTOCHROME P450 DRUG INTERACTION RISK FOR ONC201 USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING
Tim Tippin
Favorite
Tran, Clayton

University of California, San Diego
PII-083 - PHARMACOGENOMIC ANALYSIS OF THE PHARMACOKINETIC ENDPOINTS FROM A DRUG-DRUG INTERACTION STUDY OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN CANCER PATIENTS.
Clayton Tran
Favorite
Tran, Lana

Pfizer, Inc.
PII-157 - THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS (PK) OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, IN HEALTHY ADULT PARTICIPANTS.
Lana Tran
Favorite
Tran, Tony

ORISE
PII-192 - SAFETY CONSIDERATIONS OF SUBJECT POPULATION SELECTION IN BIOEQUIVALENCE STUDIES FOR GENERIC DRUG DEVELOPMENT.
Tony Tran
Favorite
V
Valle, Kostandin

University of Missouri-Columbia School of Medicine
PII-074 - BIPOLAR DISORDER GWAS IDENTIFIED A SNP SIGNAL IN THE THSD7A GENE THAT IS ASSOCIATED WITH RESPONSE TO VALPROATE AND LAMOTRIGINE.
Kostandin Valle
Favorite
van Borselen, Marjolein

Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud university medical center
LB-035 - TOWARDS MORE ROBUST EVALUATION OF THE PREDICTIVE PERFORMANCE OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS: USING CONFIDENCE INTERVALS TO SUPPORT USE OF MODEL-INFORMED DOSING IN CLINICAL CARE
Marjolein van Borselen
Favorite
van der Heijden, Joyce

Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud university medical center -
CT-001 - AGE-APPROPRIATE DOSING FOR DEXAMETHASONE TO PREVENT POST-EXTUBATION STRIDOR: A PEDIATRIC PBPK MODELING APPROACH
Joyce van der Heijden
Favorite
PII-160 - AGE-APPROPRIATE DOSING FOR DEXAMETHASONE TO PREVENT POST-EXTUBATION STRIDOR: A PEDIATRIC PBPK MODELING APPROACH
Joyce van der Heijden
Favorite
van Haarst, Aernout

Celerion
PII-140 - PHARMCOKINETIC AND PHARMACODYNAMIC RELATIONSHIPS OF INTRANASALLY ADMINISTERED AND INTRAMUSCULARLY INJECTED EPINEPHRINE
Aernout van Haarst
Favorite
Velasquez, Erick

Genentech
PT-008 - PREDICTION OF OVERALL SURVIVAL IN MELANOMA PATIENTS: A TUMOR GROWTH INHIBITION OVERALL SURVIVAL MODELING FRAMEWORK
Erick Velasquez
Favorite
PWII-005 - PREDICTION OF OVERALL SURVIVAL IN MELANOMA PATIENTS: A TUMOR GROWTH INHIBITION OVERALL SURVIVAL MODELING FRAMEWORK
Erick Velasquez
Favorite
W
Wang, Meijie

Mayo Clinic
PII-045 - ACETYLATION-DEPENDENT REGULATION OF NUCLEAR PD-L1 IS CRITICAL TO SISTER CHROMATID COHESION IN TRIPLE NEGATIVE BREAST CANCER
Meijie Wang
Favorite
Wang, Min

Mayo Clinic
PII-084 - PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: A GENETIC DETERMINANT OF MYOCARDIAL RECOVERY
Min Wang
Favorite
wang, xue

wang.xue2@mayo.edu
PII-075 - DNA METHYLTRANSFERASE INHIBITOR SYNERGIZE WITH IMMUNE CHECK POINT INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
xue wang
Favorite
Wilk, Jordan

University of Florida
PII-179 - A COMPUTATIONAL TOOL TO OPTIMIZE CLINICAL TRIAL DESIGN FOR DUCHENNE MUSCULAR DYSTROPHY: A PRACTICAL GUIDE AND CASE STUDIES.
Jordan Wilk
Favorite
Winfield, Jordan

The University of Texas at El Paso
PII-031 - REVIEW OF TRANSLATIONAL CANCER RESEARCH TARGETING ADENOSINE RECEPTOR A2AR.
Jordan Winfield
Favorite
Wong, Hansen

Amgen
PII-103 - CLINICAL PHARMACOLOGY CHARACTERIZATION OF BLINATUMOMAB FROM SUBCUTANEOUS (SC) DOSING IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Hansen Wong
Favorite
Wu, Fan

Bristol Myers Squibb
PII-017 - CHARACTERIZING CELLULAR KINETICS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
Fan Wu
Favorite
Wu, Fang

U.S. Food and Drug Administration
PII-163 - APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING TO SUPPORT BIOEQUIVALENCE EVALUATION OF MESALAMINE DELAYED RELEASE TABLETS
Fang Wu
Favorite
Wu, Xiaojie

Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China
PII-132 - PHARMACOKINETICS AND SAFETY OF MAVACAMTEN IN HEALTHY CHINESE SUBJECTS WITH DIFFERENT CYP2C19 PHENOTYPES
Xiaojie Wu
Favorite
X
Xiao, Jingcheng

Merck & Co., Inc.
PII-152 - PREDICT: A MACHINE LEARNING ALGORITHM FOR PREDICTING PHARMACOKINETIC PROFILES
Jingcheng Xiao
Favorite
Xu, Donghong

Cytokinetics, Incorporated, South San Francisco, CA
CT-002 - EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF AFICAMTEN AND ITS METABOLITES.
Donghong Xu
Favorite
PII-111 - DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF STRONG CYP3A INHIBITION AND P450 INDUCTION ON THE PHARMACOKINETICS OF AFICAMTEN, AND THE EFFECT OF AFICAMTEN ON P-GLYCOPROTEIN, IN HEALTHY PARTICIPANTS.
Donghong Xu
Favorite
PII-200 - EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF AFICAMTEN AND ITS METABOLITES.
Donghong Xu
Favorite
Xu, Yue

The Ohio State Univerity
PII-042 - DEVELOPMENT OF A NOVEL FLUORESCENCE-BASED APPROACH FOR SOLUTE CARRIER-FOCUSED CRISPR/CAS9 KNOCKOUT SCREENING IN BREAST CANCER CELLS
Yue Xu
Favorite
Y
Yang, Derek

Pfizer, Inc.
PII-158 - THE EFFECT OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, ON DABIGATRAN PHARMACOKINETICS (PK) IN HEALTHY ADULT PARTICIPANTS.
Derek Yang
Favorite
Yang, Eunsol

University of California, San Francisco
OAII-003 - A LONGITUDINAL HBA1C MODEL IN PATIENTS WITH TYPE 2 DIABETES ELUCIDATES THE ROLE OF CODING VARIANT IN GLUCOSE TRANSPORTER GENE, SLC2A2, ON GLYCEMIC RESPONSE TO METFORMIN.
Eunsol Yang
Favorite
PT-003 - A LONGITUDINAL HBA1C MODEL IN PATIENTS WITH TYPE 2 DIABETES ELUCIDATES THE ROLE OF CODING VARIANT IN GLUCOSE TRANSPORTER GENE, SLC2A2, ON GLYCEMIC RESPONSE TO METFORMIN.
Eunsol Yang
Favorite
Yang, Jianning

Astellas Pharma, Inc.
PII-066 - POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES OF ZOLBETUXIMAB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Jianning Yang
Favorite
Yan, Li

NGM Biopharmaceuticals
PII-144 - POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF NGM707, AN ILT2/ILT4 DUAL ANTAGONIST ANTIBODY IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
Li Yan
Favorite
PII-147 - POPULATION PHARMACOKINETIC MODELING OF NGM438 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
Li Yan
Favorite
Yoon, Deok Yong

Novartis
PT-020 - USE OF QUANTITATIVE MAGNETIC RESONANCE IMAGING BIOMARKERS IN CLINICAL TRIALS FOR DUCHENNE MUSCULAR DYSTROPHY: MULTIVARIATE DISEASE PROGRESSION MODELS BRIDGING TIMED MOTOR FUNCTION TESTS AND FAT FRACTION
Deok Yong Yoon
Favorite
PWI-003 - USE OF QUANTITATIVE MAGNETIC RESONANCE IMAGING BIOMARKERS IN CLINICAL TRIALS FOR DUCHENNE MUSCULAR DYSTROPHY: MULTIVARIATE DISEASE PROGRESSION MODELS BRIDGING TIMED MOTOR FUNCTION TESTS AND FAT FRACTION
Deok Yong Yoon
Favorite
Yuan, Jiajia

Peking University Cancer Hospital and Institute
PII-134 - PHARMACOKINETICS OF INFIGRATINIB AND ITS ACTIVE METABOLITES IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA HARBORING FGFR2 GENE AMPLIFICATION
Jiajia Yuan
Favorite
Yu, Chongwoo

Division of Cardiometabolic and Endocrine Pharmacology, Office of Clinical Pharmacology, U.S. Food and Drug Administration
PII-191 - PEDIATRIC CLINICAL TRIAL DESIGNS FOR TESTOSTERONE REPLACEMENT THERAPY.
Chongwoo Yu
Favorite
Yue, Min

Purdue University
OAI-004 - ORAL PROGESTERONE-MEDIATED ATTENUATION OF IBUTILIDE-INDUCED QT INTERVAL LENGTHENING IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN: POPULATION PHARMACOKINETIC/ PHARMACODYNAMIC MODEL
Min Yue
Favorite
PT-028 - ORAL PROGESTERONE-MEDIATED ATTENUATION OF IBUTILIDE-INDUCED QT INTERVAL LENGTHENING IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN: POPULATION PHARMACOKINETIC/ PHARMACODYNAMIC MODEL
Min Yue
Favorite
Z
Zaidi, Syed Saoud

Indiana University
PT-025 - DEVELOPMENT AND VERIFICATION OF A NIFEDIPINE CONTROLLED RELEASE PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL IN PREGNANCY
Syed Saoud Zaidi
Favorite
Zhang, Rong

Genentech
PII-033 - EXPANDING THE USE OF REAL-WORLD DATA TO ANSWER CLINICAL PHARMACOLOGY QUESTIONS: DEVELOPMENT OF A USER-FRIENDLY DASHBOARD TO ASSESS PREVALENCE OF ORGAN IMPAIRMENT IN PATIENTS IN THE REAL-WORLD SETTING.
Rong Zhang
Favorite
Zheng, Zicong

University of Houston
TIP-003 - EVALUATING THE IMPACT OF XIAO-CHAI-HU-TANG ON PHARMACOKINETIC BEHAVIORS OF IRINOTECAN, RALOXIFENE AND THEIR METABOLITES IN HUMANS: A RUN-IN SAFETY STUDY.
Zicong Zheng
Favorite
Zhou, Jian

Bristol Myers Squibb
PII-101 - CHARACTERIZING EXPOSURE-RESPONSE RELATIONSHIPS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
Jian Zhou
Favorite
Zhou, Jieqiang

University of Florida
PII-150 - POPULATION PHARMACOKINETICS OF ENROFLOXACIN AND FLORFENICOL IN THE GIANT DANIO (DEVARIO AEQUIPINNATUS) FOLLOWING ORAL AND BATH ADMINISTRATION
Jieqiang Zhou
Favorite
Zhou, Li

Pfizer, Inc.
PII-115 - EVALUATION OF THE EFFECT OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, ON ROSUVASTATIN PHARMACOKINETICS (PK) IN HEALTHY ADULT PARTICIPANTS.
Li Zhou
Favorite
Zhou, Lian

ARCUS Biosciences
LB-011 - DEVELOPMENT AND VERIFICATION OF MECHANISTIC PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL FOR ENZALUTAMIDE AND ITS N-DESMETHYL METABOLITE M2 AS INDUCERS OF CYP3A4
Lian Zhou
Favorite
Zhu, Min

Regeneron Pharmaceuticals, Inc.
PII-053 - EVALUATION OF IMPACT OF PRIOR CAR T THERAPY ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL).
Min Zhu
Favorite
Zhu, Xiujuan

Mayo Clinic
OAII-002 - ALCOHOL USE DISORDER PHARMACOGENOMICS: ROLE OF FNDC4 IN HUMAN NEURONAL FUNCTION.
Xiujuan Zhu
Favorite
PT-010 - ALCOHOL USE DISORDER PHARMACOGENOMICS: ROLE OF FNDC4 IN HUMAN NEURONAL FUNCTION.
Xiujuan Zhu
Favorite
Zou, Peng

Daiichi Sankyo
PII-198 - CLINICAL PHARMACOLOGY CONSIDERATIONS IN EXTRAPOLATION OF EFFICACY AND SAFETY FROM ADULTS TO PEDIATRICS - LESSONS LEARNED FROM PEDIATRIC PROGRAMS OF DIRECT ORAL ANTICOAGULANTS.
Peng Zou
Favorite